AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-III HARMONIZE trial in Patients with Hyperkalaemia
Shots:
- The global P-III HARMONIZE involves assessing of Lokelma (5/10mg) vs PBO in 267 patients with hyperkalaemia in Japan- Korea- Taiwan and Russia across 47 locations
- P-III HARMONIZE Results: @48 hrs.: Achieved normokalaemia (mean K level 3.5-5.0 mEq/L) 93%; safety was consistent with previous trials. These results will support its registration in Japan- Korea- Taiwan and Russia- are presented at ASN Kidney Week-2018
- Lokelma is currently approved in adults for hyperkalemia in the US & EU. In 2015- AZ acquired Lokelma from ZS pharma
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com